Tracy Burgess

1.4k total citations · 1 hit paper
19 papers, 1.1k citations indexed

About

Tracy Burgess is a scholar working on Epidemiology, Surgery and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Tracy Burgess has authored 19 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Epidemiology, 7 papers in Surgery and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Tracy Burgess's work include Lipoproteins and Cardiovascular Health (6 papers), Influenza Virus Research Studies (4 papers) and Cancer, Lipids, and Metabolism (3 papers). Tracy Burgess is often cited by papers focused on Lipoproteins and Cardiovascular Health (6 papers), Influenza Virus Research Studies (4 papers) and Cancer, Lipids, and Metabolism (3 papers). Tracy Burgess collaborates with scholars based in United States, Switzerland and United Kingdom. Tracy Burgess's co-authors include David Kallend, Evan A. Stein, Christie M. Ballantyne, Michael E. Farkouh, James H.F. Rudd, Zahi A. Fayad, Ahmed Tawakol, Valentı́n Fuster, Mark Woodward and Venkatesh Mani and has published in prestigious journals such as The Lancet, Nature Medicine and Journal of the American College of Cardiology.

In The Last Decade

Tracy Burgess

19 papers receiving 1.0k citations

Hit Papers

Safety and efficacy of dalcetrapib on atherosclerotic dis... 2011 2026 2016 2021 2011 100 200 300

Peers

Tracy Burgess
Comparison fields: 5 of 77
  • Surgery 444
  • Endocrinology, Diabetes and Metabolism 282
  • Epidemiology 266
  • Cardiology and Cardiovascular Medicine 204
  • Radiology, Nuclear Medicine and Imaging 195
Replace Phaik‐Leng Cheah with:
Phaik‐Leng Cheah Malaysia
Ziad Younes United States
Ming‐Lun Yeh Taiwan
Shingo Tanaka Japan
Megumu Fujihara Japan
Brian B. Borg United States
Davide Bitetto Italy
Minneke J. Coenraad Netherlands
Yuki Kojima Japan
E. Cofrancesco Italy
Phaik‐Leng Cheah Malaysia View profile →
Citations per field, relative to Tracy Burgess
Tracy Burgess · 1×
Citations per year, relative to Tracy Burgess
Tracy Burgess · 1×

Countries citing papers authored by Tracy Burgess

Since Specialization
Citations

This map shows the geographic impact of Tracy Burgess's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tracy Burgess with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tracy Burgess more than expected).

Fields of papers citing papers by Tracy Burgess

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tracy Burgess. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tracy Burgess. The network helps show where Tracy Burgess may publish in the future.

Co-authorship network of co-authors of Tracy Burgess

This figure shows the co-authorship network connecting the top 25 collaborators of Tracy Burgess. A scholar is included among the top collaborators of Tracy Burgess based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tracy Burgess. Tracy Burgess is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
# Work Indexed citations
1 25
2 94
3 2
4 22
5 10
6 60
7 75
8 44
9 33
10 1
11 49
12
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial breakdown →
377
13 39
14 7
15 1
16 83
17 24
18
Safety and Tolerability of Dalcetrapib††Conflicts of interest: Dr. Stein has received grants for studies of lipid-modifying agents, has received consulting fees and honoraria for professional input regarding agents to modify lipid profile, and/or has delivered lectures for the American Association for Clinical Chemistry, Washington, District of Columbia; Abbott Laboratories, Abbott Park, Illinois; AstraZeneca, Wilmington, Delaware; the United States Food and Drug Administration, Washington, District of Columbia; F. Hoffmann-La Roche Ltd., Basel, Switzerland; Isis Pharmaceuticals, Inc., Carlsbad, California; Merck & Co., Whitehouse Station, New Jersey; the National Lipid Association, Jacksonville, Florida; Novartis International AG, Basel Switzerland; Reliant Pharmaceuticals, Inc., Liberty Corner, New Jersey; Daiichi Sankyo Co., Ltd., Tokyo, Japan; Schering-Plough Corporation, Kenilworth, New Jersey; Takeda Pharmaceutical Company Ltd., Osaka, Japan; and Wyeth, Madison, New Jersey. Dr. Stroes has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. and Novartis International AG. Dr. Steiner has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd.; Solvay, Brussels, Belgium; Ethypharm S.A., Saint-Cloud, France; and Merck Frosst Canada Ltd. (Kirkland, Quebec, Canada)/Schering-Plough Corporation. Dr. Buckley has received research grants from AstraZeneca; Merck Sharp & Dohme, Dublin, Ireland; and Pfizer, Inc., New York, New York. Dr. Buckley has received honoraria and consulting fees and/or delivered lectures for AstraZeneca; Bristol-Myers Squibb, New York, New York; F. Hoffmann-La Roche Ltd.; Novartis International AG; Pfizer, Inc.; and Sanofi-Aventis, Paris, France. Dr. Capponi has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. Dr. Burgess is an employee of Hoffmann-La Roche Inc., Nutley, New Jersey. Drs. Niesor and Kallend are employees of F. Hoffmann-La Roche Ltd. Dr. Kastelein has received research grants, honoraria, or consulting fees for professional input and/or has delivered lectures for Pfizer, Inc.; Merck Sharp & Dohme; F. Hoffmann-La Roche Ltd.; Novartis International AG; Isis Pharmaceuticals, Inc.; Kowa Pharmaceutical Company Ltd., Nagoya, Japan; Schering-Plough Corporation; and AstraZeneca.
104
19 14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026